"
Team:Wageningen UR
From 2012.igem.org
(Difference between revisions)
TSlijkhuis (Talk | contribs) |
|||
| Line 23: | Line 23: | ||
<h4>A standardized tool for site specific drug delivery using Virus-Like Particles</h4> | <h4>A standardized tool for site specific drug delivery using Virus-Like Particles</h4> | ||
<p align="justify">Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.</p> | <p align="justify">Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.</p> | ||
| - | |||
| - | |||
</div> | </div> | ||
Revision as of 12:11, 20 September 2012
[hier komt het intro filmpje, met op het eind een link naar Project Overview]
Abstract
A standardized tool for site specific drug delivery using Virus-Like Particles
Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.
The Constructor
An application that assists you in creating your cloning strategies for your iGEM project.
The Team
Social Stream
Tweets by @igemwageningenMedal Achievements
We helped the iGEM community by providing The Constructor.
This a tool which makes constructing complicated Functional Genetic Modules build from many BioBrick child’s play. The trials showed a more efficient cloning strategy which saves time in the laboratory work.
We improved one of the most widely used BioBricks.
The reporter protein GFP[link to PnA??] has been modified to attach specifically to any protein. By using the PnA System, the GFP can be used to indicate the location of, for example, expressed receptors.
We turned the Human Practices[link Human practices] into a national effort.
By cooperating with most of the Dutch iGEM teams, we managed to have a nation-wide appearance in three major cities during the Discovery Festivals [link website R’dam]. Our team presents the science of iGEM in Rotterdam, while being analysed by a student in Applied Communication [link Paulien].
We submitted a new and well characterised standard BioBrick: CCMV wt [link to BioBrick Code]
This BrioBrick can be used to produce wild type CCMV Virus-Like particles. Besides, it can serve as a template for modifications to pursue many new applications (link to apps). The sequence is confirmed.
We demonstrated that the production of VLPs using our own BioBricks works.
We produced both CCMV and HepB VLPs using the BioBricks we constructed ourselves. The protocol and detailed description of the machines used for production and detection of these VLPs had been made available [link]
We characterised the stability [link work Mark] of CCMV VLPs.
We changed the conditions in which the VLPs were dissolved. By changing pH and temperature and taking samples over time, we indicated at which values the VLPs were not stable. This defines the borders at which the VLPs can be used.
Team registration
New submitted and highly-documented standard BioBrick Part or Device.
Complete Judging form
Team Wiki
Present a poster and a talk at the iGEM Jamboree
